Phosphorylation of Serine Residues 3, 6, 10, and 13 Distinguishes Membrane Anchored from Soluble Glutamic Acid Decarboxylase 65 and Is Restricted to Glutamic Acid Decarboxylase 65alpha *

(Received for publication, August 1, 1996, and in revised form, October 25, 1996)

Mark Namchuk Dagger §, LeAnn Lindsay Dagger , Christoph W. Turck , Jamil Kanaani Dagger and Steinunn Baekkeskov Dagger

From the Dagger  Department of Medicine, Department of Microbiology and Immunology, and Hormone Research Institute and the  Howard Hughes Medical Institute, and Department of Medicine, University of California San Francisco, San Francisco, California 94143

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

GAD65, the smaller isoform of the gamma -aminobutyric acid-synthesizing enzyme glutamic acid decarboxylase is detected as an alpha /beta doublet of distinct mobility on SDS-polyacrylamide gel electrophoresis. Glutamic acid decarboxylase (GAD) 65 is reversibly anchored to the membrane of synaptic vesicles in neurons and synaptic-like microvesicles in pancreatic beta -cells. Here we demonstrate that GAD65alpha but not beta  is phosphorylated in vivo and in vitro in several cell types. Phosphorylation is not the cause of the alpha /beta heterogeneity but represents a unique post-translational modification of GAD65alpha . Two-dimensional protein analyses identified five phosphorylated species of three different charges, which are likely to represent mono-, di-, and triphosphorylated GAD65alpha in different combinations of phosphorylated serines. Phosphorylation of GAD65alpha was located at serine residues 3, 6, 10, and 13, shown to be mediated by a membrane bound kinase, and distinguish the membrane anchored, and soluble forms of the enzyme. Phosphorylation status does not affect membrane anchoring of GAD65, nor its Km or Vmax for glutamate. The results are consistent with a model in which GAD65alpha and -beta constitute the two subunits of the native GAD65 dimer, only one of which, alpha , undergoes phosphorylation following membrane anchoring, perhaps to regulate specific aspects of GAD65 function in the synaptic vesicle membrane.


INTRODUCTION

Glutamic acid decarboxylase (GAD)1 (EC 4.1.1.15) catalyzes the alpha -decarboxylation of glutamate generating gamma -aminobutyric acid (GABA). GABA is a major inhibitory neurotransmitter in the central nervous system (1), and may also act as a paracrine signaling molecule in pancreatic islets, where it is synthesized in beta -cells (2, 3). GABA can also function as a metabolic intermediate and be fueled into the Krebs cycle via the GABA shunt (4, 5). In mammalian species two highly homologous non-allelic forms of the enzyme have been identified and designated GAD65 and GAD67 in accordance with their relative molecular masses in kDa (6, 7). GAD65, but not GAD67, is unusually susceptible to becoming an autoantigen in two human diseases that affect its major sites of expression, pancreatic beta -cells and GABA-ergic neurons. Thus GAD65 is a major autoantigen in insulin-dependent diabetes mellitus in man (8), and the non-obese diabetic mouse (9, 10), and in a rare neurological disease, stiff-man syndrome in man (11).

GAD65 and GAD67 differ with regard to their steady state saturation with the co-enzyme pyridoxal 5'-phosphate (PLP). At least 50% of GAD in brain is present as the PLP free apoenzyme (12, 13). GAD65 constitutes the majority of this enzyme reservoir (14), which can be activated by influx of co-factor, or perhaps by targeting the protein to compartments in the cell where PLP is available. In contrast to GAD65, the majority of GAD67 seems to be perpetually saturated with PLP (14).

The efficacy of neurotransmitter production by GAD65 may also be regulated by its subcellular location. GAD65 is isolated both in a cytosolic and a firmly membrane anchored form (15, 16). The enzyme is synthesized as a cytosolic soluble protein, but undergoes a stepwise post-translational modification in the NH2-terminal domain to become hydrophobic and anchored to synaptic vesicle-like microvesicles (16, 17). The modifications involve palmitoylation of cysteines 30 and 45, but this modification is not essential for membrane anchoring of the protein in COS-7 cells (18). Membrane anchoring is reversible, suggesting that trafficking of GAD65 between membranes and cytosol may regulate its proximity to synaptic vesicles and the efficacy by which its product GABA can be accumulated for secretion (16). Association of GAD65 with vesicles could place the protein in the proximity of a hypothetical GABA transporter, perhaps serving the double function of loading the neurotransmitter into the vesicle that secretes it, as well as removing GABA from the proximity of the enzyme, to prevent product inhibition of enzyme activity (19).

GAD purified from rat, pig, and human brain under native conditions forms dimers (20-22). The native form of both GAD65 and GAD67 is a non-covalently associated homodimer detected by gel filtration and native gel electrophoresis.2 Both the GAD67 and GAD65 dimers dissociate into monomers on SDS-PAGE under either reducing or nonreducing conditions. Reducing SDS-PAGE resolves GAD65 but not GAD67 into two bands of distinct mobility, which have been designated alpha  and beta  (15, 16, 23). The nature of the differences between alpha  and beta  is not known. Both alpha  and beta are palmitoylated, their ratio is always identical in different subcellular fractions and no differences have been detected in their hydrophobicity (15, 16).

Two-dimensional gel electrophoretic studies of GAD65 in human and rat islets (15, 23, 24) and brain (8) in the presence of enzyme inhibitors suggested to us that the protein might be phosphorylated. The present study demonstrates that GAD65 is phosphorylated in vivo as well as in vitro, that phosphorylation distinguishes GADalpha and -beta , and is a prominent modification of the membrane anchored, but not the cytosolic form of the enzyme.


MATERIALS AND METHODS

Site-directed Mutagenesis

Oligonucleotide-mediated mutagenesis of serines in the NH2-terminal region and deletion of the first 8 and 15 amino acids of rat GAD65 (rGAD65), respectively, were described previously (18, 25). Oligonucleotide-mediated mutagenesis of individual serine residues 3, 6, 10, 13, 17, and 20 in human GAD65 (hGAD65) was performed by the method of Kunkel (26). The S3A/S6A/S10A/S13A mutant was generated in two steps, by first constructing a S3A/S6A mutant, generating a single stranded cDNA, and undertaking a second round of mutagenesis to convert serines 10 and 13 to alanine. The template for these mutants was the hGAD65 cDNA cloned into a Bluescript S/K vector (18).

For expression in COS-7 cells (Life Technologies, Inc., Gaithersburg, MD), mutant hGAD65 cDNAs were subcloned into the SV40-based expression vector pSVsport (Life Technologies, Inc.) at the EcoRI and XbaI sites. For expression in BHK-21 cells (Life Technologies, Inc.), PC12 cells (American Type Tissue Collection, Rockville, MD), and beta TC3 cells (27), wild type hGAD65, and the S3A/S6A/S10A/S13A mutant were subcloned into the cytomegalovirus based vector pcDNA3 (Invitrogen, San Diego, CA) at the EcoRI, and XBaI sites.

Cell Lines and Expression of Recombinant Wild-type and Mutant GAD65

Baby hamster kidney cells (BHK-77-3) stably expressing hGAD65 (a generous gift from W. Hagopian, University of Washington) were derived from tk- ts13 BHK cells (28), which were originally isolated as temperature-sensitive BHK-21 cells. BHK-77-3 cells were cultured in Dulbecco's modified Eagle's medium, supplemented with 10% fetal calf serum, glutamine (2 mM), penicillin (100 units/ml), streptomycin (100 µg/ml), and 800 nM methotrexate. COS-7 cells were grown in the same medium as BHK-77-3 cells but without methotrexate. Transient expression of wild-type and mutant hGAD65 or rGAD65 in COS-7 cells was obtained by LipofectAMINE (Life Technologies, Inc.) assisted transfection using 15 µg of plasmid DNA and 57 µl of LipofectAMINE (per 10-cm plate of cells) in Opti-MEM I (Life Technologies, Inc.). Cells were refreshed with Dulbecco's modified Eagle's medium 10-12 h after transfection and cultured for additional 48 h before harvesting. BHK-21 cells were cultured in Glasgow minimal essential medium, BHK-21 (Life Technologies, Inc.), supplemented with 10% tryptose phosphate, 10% fetal calf serum, penicillin (100 units/ml), and streptomycin (100 µg/ml). Transient expression of protein in BHK-21 cells was achieved in a similar manner as in COS-7 cells, except using 20 µg of pCDNA3 constructs. PC12 cells were cultured and transfected as described by Bonzelius et al. (29). beta TC3 cells were cultured as described previously (27). Transient expression of protein in beta TC3 cells was achieved in a similar manner as in COS-7 cells except using Cellfectin (Life Technologies, Inc.) mediated transfer of pcDNA3 constructs. hGAD65 was expressed from a baculovirus construct in Sf9 cells as described previously (16).

Antisera

GAD6, a mouse monoclonal antibody specific for GAD65, and 1701, a rabbit antiserum that recognizes an epitope in the carboxyl terminus of GAD65 and GAD67, were described previously (30). Rabbit antiserum to glucagon (DAKO, Carpintera, CA) and normal mouse serum (Sigma) were used as control sera.

32P, 33P, and 35S Labeling in Vivo

For phosphorylation experiments BHK-77-3 cells or transfected COS-7 cells were grown to 80-90% confluency in a 10-cm plate, rinsed twice in phosphate-free Dulbecco's modified Eagle's medium (Life Technologies, Inc.) containing 1% dialyzed fetal calf serum, and for BHK-77-3 cells 800 nM methotrexate and incubated in the same medium for 2 h. The cells were then rinsed three times in the same medium and incubated in 5 ml of fresh medium containing 4 mCi of [32P]- or [33P]orthophosphate (ICN, Costa Mesa, CA) for 3 h. Metabolic labeling of cellular proteins with [35S]methionine (Amersham) was described previously (31). Labeled cells were washed twice in phosphate-buffered saline, and lysed in 0.5 ml of HMAP buffer (10 mM HEPES/NaOH, pH 7.4, 1 mM MgCl2, 1 mM 2-aminoethylisothiouronium bromide, 0.2 mM PLP, containing 0.1 mM p-chloromercuriphenyl sulfonic acid, 1 mM phenylmethylsulfonyl fluoride, 10 mM benzamidine, 0.1 mM Na3VO4, 5 mM ETDA, 5 mM sodium fluoride, and 1% Triton X-114 (HMAP-PIT buffer) for 30 min. The lysate was centrifuged at 15,000 × g for 30 min. GAD65 was immunoprecipitated from the supernatant by incubation with the GAD6 antibody for 2 h, and isolation of the immune complexes using protein A-Sepharose (Pharmacia, Uppsala, Sweden). Immunoprecipitates were washed seven times, and eluted from protein A-Sepharose by one of two methods. For one-dimensional SDS-PAGE on 10% polyacrylamide gels, samples were boiled for 3 min in SDS sample buffer (23). For two-dimensional gel electrophoresis using non-equilibrium pH-gradient gel electrophoresis (NEPHGE) in the first dimension and 10% SDS-PAGE in the second dimension, washed immunoprecipitates were incubated at 28 °C for 3 min in an urea/Nonidet P-40 buffer followed by centrifugation to remove the protein A-Sepharose beads. The NEPHGE/SDS-PAGE two-dimensional analysis was carried out as described elsewhere (15, 23). The polyacrylamide gels were dried and analyzed by autoradiography (32P, 33P) or fluorography (35S). Alternatively, proteins were transferred from gels by Western blotting to Immobilon-P membranes (Millipore, Bedford, MA) and immunostained with the 1701 antibody as described previously (30). Antibody staining was visualized with either an alkaline phosphatase-coupled secondary antibody (Zymed, S. San Francisco, CA), or chemiluminescent detection using a horseradish peroxidase-coupled secondary antibody (Vector Labs, Burlingame, CA) and the ECL system (Amersham, Buckinghamshire, United Kingdom). Western blots were also analyzed by autoradiography.

In Vitro Phosphorylation

A 90-100% confluent 10-cm (inner diameter) plate of BHK-77-3 cells, transfected COS-7 cells, or infected Sf9 cells was harvested in 0.5 ml of HMAP buffer containing 1 mM phenylmethylsulfonyl fluoride and 0.1 mM p-chloromercuriphenyl sulfonic acid (HMAP-P buffer). The cells were lysed on ice using a glass homogenizer, warmed to 37 °C, and incubated for an additional 5 min at the same temperature in the presence of 150 µCi of [gamma -32P]ATP (30 Ci/mmol, Amersham). Labeled samples were cooled on ice for 5 min and supplemented with 100 µl of HMAP-P buffer containing EDTA, sodium fluoride, Na3VO4, and Triton X-114 to yield final concentrations similar to those in HMAP-PIT buffer, extracted for 30 min and cleared by centrifugation at 15,000 × g for 30 min. The supernatants were immunoprecipitated and analyzed by SDS-PAGE.

Phosphoamino Acid Analysis

In vivo 32P-labeled hGAD65 was isolated by immunoprecipitation with the GAD6 antibody. The immunoprecipitates were subjected to SDS-PAGE, transferred to Immobilon-P membranes, and immunostained with the 1701 antiserum. The GAD65alpha and alpha ' bands were excised and subjected to hydrolysis for 2 h in 6 N HCl at 110 °C using a Waters Picotag hydrolysis station (Waters, Bedford, MA). Hydrolyzed samples were evaporated to dryness, re-dissolved in water, and spotted on a cellulose thin layer electrophoresis (TLE) plate (Baker, Phillipsburg, NJ). The phosphoamino acids were separated by TLE at pH 4.4 (acetone/pyridine/acetic acid/water, 8:1:2:40) on a Savant TLE apparatus (Savant, Farmingdale, NY) at constant voltage (900 V). The TLE plates were stained with ninhydrin and placed on an x-ray film (Kodak Biomax, Eastman/Kodak, Rochester, NY). Phosphoamino acids were detected by autoradiography and identified by co-migration with ninhydrin stained standards.

Two-dimensional Phosphopeptide Mapping

Tryptic phosphopeptide analyses were performed essentially as described (32). Briefly, lysates of in vivo 32P-labeled BHK-77-3 cells (10-cm plate) were immunoprecipitated with GAD6 and the immunoprecipitates subjected to SDS-PAGE followed by autoradiography of the unfixed gel. GAD65 was excised from the gel and electroeluted into 0.5 ml of 50 mM NH4HCO3, 0.1% SDS on a C.B.S. Scientific (DelMar, CA) electroelution apparatus (33). The eluted protein was lyophilized, acetone precipitated, re-dissolved in 50 µl of 50 mM ammonium bicarbonate, and digested with 8 µg of sequencing grade modified trypsin (Promega, Madison, WI) overnight at 37 °C. The tryptic digest was lyophilized, re-dissolved in water, and applied to a thin layer cellulose plate (Baker). Phosphopeptides were separated in the first dimension by electrophoresis at pH 4.4 (acetone/pyridine/acetic acid/water, 8:1:2:40) or at pH 8.9 (0.1 M ammonium carbonate) (34) on a Savant TLE apparatus at 900 V, followed by ascending chromatography in the second dimension in pyridine/1-butanol/acetic acid/water (50:75:15:60). The phosphopeptides were detected by autoradiography.

One-dimensional Tryptic Peptide Mapping

GAD65 was immunoprecipitated from Triton X-114 lysates of in vivo labeled BHK-77-3 cells and purified by electroelution as described above. The lyophilized and acetone precipitated sample was dissolved in 100 µl of 50 mM ammonium bicarbonate. A 25-µl aliquot was removed for SDS-PAGE analyses. For an extensive degradation by trypsin, the remaining sample was digested with 4 µg of modified trypsin (Promega), first at 4 °C for 5 min, and then at 37 °C overnight. Aliquots (25 µl) were removed at the two time points and quenched by boiling in SDS sample buffer. Digested samples were analyzed in triplicate lanes by Tris/Tricine non-equilibrium gel electrophoresis (35). The lanes were subjected to drying and autoradiography or immunoblotting using the 1701 antiserum.

For mild trypsin digestion to generate the 58-kDa tryptic fragment of GAD65, which contains the COOH-terminal 69/70-585 amino acids (30), GAD65 in 100 µl of 50 mM ammonium bicarbonate was treated with 0.6 µg of trypsin at 4 °C and 10-µl aliquots removed at different time points, quenched as described above, and analyzed by SDS-PAGE using 10% polyacrylamide gels, followed by immunoblotting with the 1701 antiserum.

Subcellular Fractionation Studies

Subcellular fractionation of cells was carried out using a modification of methods described previously (18). All procedures except the incubation with [gamma -32P]ATP were carried out at 4 °C.

Analysis of the subcellular distribution of phosphorylated GAD65 was carried out using in vitro or in vivo 32P-labeled BHK-77-3 cells. In vivo labeled cells were homogenized in HMAP-P buffer, containing 0.1 mM Na3VO4, and 10 mM benzamidine/HCl, and 5 mM sodium fluoride (lysis buffer). Cell homogenates were centrifuged at 800 × g to remove nuclei and cellular debris. The postnuclear supernatant was centrifuged at 150,000 × g for 1 h to separate cytosol and crude membrane fractions. The cytosolic fraction was supplemented with 5 mM EDTA and 1% Triton X-114. Sedimented membranes were resuspended in lysis buffer containing 5 mM EDTA and 0.5 M NaCl, incubated for 1 h, and resedimented by centrifugation at 150,000 × g for 1 h to separate washed membranes and a high salt wash fraction. The membrane wash fraction was supplemented with Triton X-114 to obtain a final concentration of 1%. The washed membranes were extracted in lysis buffer containing 1% Triton X-114 for 1 h followed by centrifugation at 150,000 × g for 1 h. The cytosol, washed membrane extract, and membrane wash fractions were subjected to one round of temperature-induced Triton X-114 phase separations according to Bordier (36), and the detergent and aqueous phases analyzed by immunoprecipitation, SDS-PAGE, immunoblotting, and autoradiography. In some experiments the phosphatase inhibitors, sodium fluoride and EDTA, were both present during homogenization of cells. In other experiments sodium fluoride and EDTA were absent from the lysis buffer but added together to the postnuclear spin.

For in vitro labeling experiments, BHK-77-3 cells were lysed in lysis buffer without sodium fluoride, and labeled with [gamma -32P]ATP as described in the section for in vitro labeling. 5 mM Sodium fluoride was added immediately after labeling and labeled lysates were subjected to centrifugation at 800 × g. The rest of the procedure was carried out as described above for the in vivo labeled cells.

In a different set of experiments, a cytosolic and a crude membrane fraction were prepared and labeled separately in vitro. BHK-77-3 cells were homogenized in lysis buffer without sodium fluoride, and a cytosolic and a crude membrane fraction prepared as described above. The membrane fraction was resuspended in the original volume of hypotonic lysis buffer, and both fractions were labeled in vitro with [gamma -32P]ATP. The labeled cytosolic fraction, and crude membrane suspension were cooled on ice, supplemented with 5 mM EDTA, 5 mM sodium fluoride, and 1% Triton X-114, incubated on a shaker for 30 min and centrifuged at 15,000 × g for 30 min. The supernatants were analyzed by immunoprecipitation, SDS-PAGE, immunoblotting, and autoradiography.

For comparative analysis of subcellular distribution and amphiphilicity of wild-type GAD65 and phosphorylation mutants, transiently transfected COS-7, BHK-21, PC12, or beta TC3 cells were homogenized in lysis buffer, and subjected to the subcellular fractionation procedure described above. Furthermore, transiently transfected beta TC3 cells were used for a more detailed Triton X-114 phase distribution study. Briefly subcellular fractions were subjected to two rounds of temperature-induced phase transitions using 2% Triton X-114, followed by a final wash of the aqueous phase as described by Bordier (36). The rest of the analysis was carried out as described above for the in vivo labeled material.

Dephosphorylation of GAD65

GAD65 was immunoprecipitated from in vitro labeled BHK-77-3 cell lysates prepared from two 10-cm tissue culture plates. The washed protein A-Sepharose pellet was resuspended in 50 mM Tris/HCl, pH 8.5, 0.1 mM EDTA and incubated with 5 units of calf intestinal phosphatase according to the manufacturers instructions (Boehringer Mannheim). Aliquots were removed at different intervals, boiled in SDS sample buffer, and analyzed by SDS-PAGE, immunoblotting, and autoradiography.

Enzyme Activity Measurements

Activity assays for the wild-type and mutant GAD65 proteins, generated by transient transfection in COS-7 cells, were carried out by a modification of the method described by Blindermann et al. (20). To determine the Km and Vmax for glutamate, COS-7 cells were harvested 48 h post-transfection, and lysed in 50 mM HEPES/NaOH, pH 7.0, 0.1 mM PLP, 1 mM 2-aminoethylisothiouronium bromide, 1 mM phenylmethylsulfonyl fluoride, 10 mM benzamidine/HCl, 5 mM sodium fluoride, and 0.5% Triton X-114. The lysate was centrifuged at 15,000 × g for 30 min to remove debris, and the supernatant was aliquoted and diluted 1:10 in the same buffer without Triton X-114, but containing 0.2-9 mM [1-14C]glutamate. Reactions were incubated for 1 h at 37 °C, and quenched by addition of 6 N HCl. Lysates from non-transfected COS-7 cells were used as a negative control at each substrate concentration. GAD65 protein concentrations in the different lysates were measured as percentage of wild-type protein by immunoblotting and densitometry analyses (GS-700 Imaging Densitometer, Bio-Rad) of multiple serial dilutions of each protein. Kinetic constants were calculated by a nonlinear fit to the Michaelis-Menten equation using GraFit (37). Km and Vmax values for PLP were determined in a similar manner except that cells were lyzed in the absence of PLP, the assay buffer contained 0.1% bovine serum albumin, and the reactions were carried out in 20 mM [1-14C]glutamate and at PLP concentrations between 0.1 and 20 µM.


RESULTS

GAD65 Is Phosphorylated in Vitro in Whole Cell Lysates

We initially analyzed whether hGAD65 expressed in BHK-77-3 and COS-7 cells could be phosphorylated in cellular lysates. The cells were homogenized, incubated with [gamma -32P]ATP, and the labeled protein isolated by immunoprecipitation with a GAD65 specific antibody (GAD6). The isolated protein was analyzed by SDS-PAGE and autoradiography. These experiments demonstrated that 32P-labeled GAD65 is specifically immunoprecipitated from phosphorylated cell lysates of both BHK-77-3 cells and COS-7 cells (Fig. 1A). Similar phosphorylation experiments carried out using lysates of Sf9 cells expressing GAD65 showed that GAD65 is also phosphorylated in vitro, using this material (Fig. 1B, lanes 5 and 6).


Fig. 1. GAD65 is phosphorylated in vitro and in vivo and the phosphorylated protein has a mobility similar to the alpha  component on Western blots. A, autoradiogram of immunoprecipitates of detergent extracts of in vitro [gamma -32P]ATP-labeled COS-7 and BHK cells, using the GAD65 specific monoclonal antibody GAD6 (lanes 1, 3, 5, and 7) and an anti-glucagon antibody (lanes 2, 4, 6, and 8). Lanes 1 and 2 are COS-7 cells transfected with hGAD65. Lanes 3 and 4 are untransfected COS-7 cells. Lanes 5 and 6 are BHK-77-3 cells stably expressing hGAD65. Lanes 7 and 8 are the parental BHK-21 cells which do not express GAD. MW, molecular weight markers. Phosphorylated GAD65 is specifically immunoprecipitated from transfected COS-7 and BHK-77-3 cells. B, comparison of the autoradiogram signal with the immunostaining pattern on Western blots for hGAD65 immunoprecipitated from 32P-labeled cells. GAD65 was immunoprecipitated from cells phosphorylated in vitro using [gamma -32P]ATP (lanes 1-6) or from cells labeled in vivo with [32P]phosphate (lanes 7 and 8) and the immunoprecipitates subjected to SDS-PAGE followed by Western blotting, immunostaining of the Western blots (even lanes), and autoradiography (odd lanes). The mobility of the main phosphorylated GAD65 component (32P) corresponds with that of the alpha  component on immunoblots (WB). In addition, a weak phosphorylated component, alpha ', is seen above alpha , in some experiments and co-migrates with a similar signal on the immunoblot (lanes 3 and 4). No phosphorylated band co-migrated with the GAD65beta .
[View Larger Version of this Image (67K GIF file)]


Under native conditions, GAD65 is a noncovalently associated homodimer of two 65-kDa subunits. Heating of the protein in SDS in the presence or absence of reducing agents results in dissociation of the dimer into monomer subunits.2 Under reducing conditions, high resolution SDS-PAGE and immunoblotting analyses of GAD65 reveals the doublet of GAD65 bands designated alpha  and beta  (Fig. 1B) as described earlier (15, 16, 18), and sometimes a more slowly migrating band designated alpha ' (Fig. 1B, lanes 1 and 2). Analyses of 32P autoradiograms of the immunoblots revealed one major phosphorylated band which co-migrated with the GAD65alpha band, and in some experiments, a weaker band which co-migrated with the GAD65alpha ' band. No 32P-labeled band co-migrated with GAD65beta . The co-migration of phosphorylated GAD65 with alpha , but not with beta , suggested either that phosphorylation is a cause of the alpha /beta heterogeneity or that phosphorylation is an exclusive property of alpha .

The first possibility seemed unlikely, because the presence or absence of phosphatase inhibitors in phosphorylation experiments did not seem to affect the alpha /beta ratio (data not shown). Furthermore, a treatment of GAD65 immunoprecipitated from in vitro labeled BHK-77-3 cells with calf intestinal phosphatase, resulted in a significant decrease in the 32P signal, yet the alpha /beta ratio of the protein on Western blots was not affected (data not shown). Hence, it is unlikely that phosphorylation is the principal cause of the observed alpha /beta heterogeneity. This result has been confirmed by two-dimensional protein analyses (see below).

GAD65 Is Phosphorylated in Live Cells

We next addressed the question whether GAD65 is phosphorylated in vivo. BHK-77-3 cells in culture were labeled with [32P]orthophosphate, and cell lysates were prepared and subjected to immunoprecipitation with GAD6. Immunoblotting of the immunoprecipitates revealed the GAD65 alpha /beta bands (Fig. 1B, lane 8). Autoradiography of the immunoblots demonstrated that the major in vivo phosphorylated band co-migrated with alpha  (Fig. 1B, lane 7). Thus phosphorylation seems to be restricted to GAD65alpha both in vivo and in vitro. Phosphorylation of GAD65 was severalfold more efficient in vivo than in vitro. In vivo labeled cells were therefore used for all of the following experiments except where indicated.

Evidence for Multiple Phosphorylation of GAD65

Extensive two-dimensional gel electrophoretic analyses using NEPHGE or isoelectric focusing in the first dimension and SDS-PAGE in the second dimension have been carried out to characterize GAD65 isolated from human and rat islets of Langerhans (8, 23, 30). GAD65 immunoprecipitated from total islet cell lysates or islet cell membranes frequently resolved into a series of differently charged spots in the first dimension, with the least acidic species having a pI of approximately 6.7 which corresponds to the pI calculated for the unmodified protein based on its amino acid sequence (6).

We investigated the two-dimensional pattern of phosphorylated GAD65 isolated from in vivo labeled BHK-77-3 cells, and compared it with the [35S]methionine-labeled and/or immunostained protein on Western blots (Fig. 2). GAD65 was identified in autoradiograms of total cell lysates by Western blot analysis of two-dimensional gels using the 1701 antibody, followed by autoradiography, or by comparison of the mobility of an immunoprecipitated sample of the protein, which was analyzed in a parallel run. Western blot analyses of 35S- and 33P-labeled GAD65 revealed a similar pattern of 4 differently charged spots in both GAD65alpha and beta , ranging in pI from approximately 6.7 to 6.3, and one or two spots in alpha ' of a charge similar to the most acidic spots of alpha  and beta . The two-dimensional pattern observed for GAD65alpha /beta in BHK-77-3 cells is identical to the pattern described previously for the protein in pancreatic beta -cells (23). Autoradiography of the Western blot of the 33P-labeled GAD65 and alignment of the autoradiographed and immunostained images demonstrated that all but the most basic spot in alpha  as well as all the spots in alpha ' were phosphorylated. The most basic spot in GAD65alpha and all the spots in GAD65beta were not 33P-labeled. These analyses confirm that phosphorylation is not the primary cause of the alpha /beta heterogeneity, because they reveal an unmodified alpha /beta doublet at pI 6.7. Phosphorylation, however, seems to give rise to alpha ', because all the alpha ' spots are phosphorylated and there is no unmodified alpha ' spot at pI 6.7. 


Fig. 2. Two-dimensional NEPHGE-SDS/PAGE analysis of hGAD65 from BHK-77-3 cells. Panel a, autoradiogram of a whole cell lysate of BHK-77-3 cells metabolically labeled with [35S]methionine. The locations of GAD65 alpha  and beta  were identified by alignment with GAD65 identified by immunostaining of a Western blot of an identical gel run in parallel (panel b). Panel c, immunostaining of a Western blot of GAD65 immunoprecipitated from BHK-77-3 cells, labeled in vivo with [33P]phosphate, and analyzed on a two-dimensional gel. Panel d, autoradiogram of the immunostained Western blot in panel c. There is no phosphorylation of the most basic alpha  spot, but the 33P-signal co-migrates with the other and more acidic spots in alpha and all the spots in alpha '. None of the beta  spots are phosphorylated.
[View Larger Version of this Image (55K GIF file)]


The acidic charge heterogeneity in GAD65alpha on two-dimensional gels represents the phosphorylated species. Phosphorylation is, however, clearly not the cause of the identical charge heterogeneity detected in GAD65beta . Two possibilities can be suggested to explain this result. The first is that GAD65beta undergoes an acidic modification, which does not affect the mobility on SDS-PAGE, and is distinct from phosphorylation, yet results in identical charge heterogeneity as observed for the phosphorylated GAD65alpha . Although this possibility cannot be formally excluded it seems unlikely, based on extensive two-dimensional analysis of GAD65 isolated from pancreatic beta -cells in different conditions, which preserved the charge heterogeneity or phosphorylation of GAD65alpha to a varying degree (15, 23, 30). In every analysis the charge heterogeneity of GAD65beta has been the exact replica of the GAD65alpha pattern, inferring that if GAD65beta indeed undergoes a series of distinct acidic modifications they would (i) result in identical charge heterogeneity as that imposed by phosphorylation of alpha  in all cases; and (ii) be of identical stability as the phosphorylation of alpha  in a variety of conditions. The probability of a distinct acidic modification that so closely resembles phosphorylation is low. The most likely explanation is that beta  does not undergo an acidic modification, but that alpha and beta  constitute the two subunits of the GAD65 dimer. The GAD65 dimer is stable in non-ionic detergent and urea2 and is therefore unlikely to dissociate during electrophoresis in the NEPHGE dimension. It will, however, come apart under the strongly dissociating conditions of the SDS-PAGE dimension. The charge heterogeneity detected in beta  in the NEPHGE dimension on two-dimensional gels would therefore not reflect its own heterogeneity, but that of the native GAD65 dimer.

The two-dimensional gel electrophoretic data strongly suggest that phosphorylation is an exclusive property of alpha . Thus the acidic charge heterogeneity in alpha  would result from phosphorylation of one, two, and three amino acid residues, respectively, without significantly affecting the SDS-PAGE mobility, whereas the phosphorylated spots in alpha ' may represent double and/or triple phosphorylation of a different combination of amino acids in GAD65alpha resulting in a slight mobility shift on SDS-PAGE. It is also possible that the modification of GAD65 is restricted to mono- and diphosphorylation of the protein, but that the triple charge heterogeneity is caused by differences in protonation of the phosphate groups at the near neutral pH of GAD65 (38).

GAD65 Is Phosphorylated on Multiple Serine Residues in the NH2-terminal Domain

The amino acid residue(s), which undergo phosphorylation in the GAD65 protein, were characterized by phosphoamino acid analyses. GAD65 from in vivo phosphorylated BHK-77-3 cells was purified, subjected to hydrolysis in 6 N HCl, and amino acids were separated by thin layer electrophoresis. Phosphorylated amino acids were detected by autoradiography. Those analyses detected only one phosphorylated amino acid which was identified as phosphoserine (Fig. 3, panel A). Thus GAD65 seems to undergo phosphorylation exclusively on serine residue(s).


Fig. 3. GAD65 is phosphorylated on serine residue(s) which may reside in the same tryptic fragment. A, autoradiogram of a TLE analyses of amino acids generated by hydrolysis of hGAD65 purified from in vivo phosphorylated BHK-77-3 cells. P-S, P-T, and P-Y indicate the location of phosphoserine, phosphothreonine, and phosphotyrosine standards; Pi, inorganic phosphate. B, autoradiograms of two-dimensional TLE/TLC analysis of tryptic fragments of hGAD65 purified from in vivo phosphorylated BHK-77-3 cells using TLE at pH 4.4 (top panel) and 8.9 (bottom panel), respectively. TLE at pH 8.9 enhances the separation of differently charged peptides and resolves the single spot detected at pH 4.4 into three species indicated by arrows.
[View Larger Version of this Image (38K GIF file)]


We next assessed the distribution of phosphorylation sites in GAD65 by two-dimensional phosphopeptide mapping. 32P-Labeled GAD65 was purified from BHK-77-3 cells and subjected to tryptic digestion followed by two-dimensional separation of peptides by TLE at pH 4.4 or 8.9 in the first dimension, and TLC in the second dimension. Labeled peptides were detected by autoradiography. TLE at pH 4.4 revealed a single phosphorylated spot on the two-dimensional plate, suggesting that the phosphorylation sites may reside in a single peptide (Fig. 3B, top panel). Identical results were obtained for hGAD65 expressed in COS-7 cells (results not shown). TLE at pH 8.9, which enhances the separation of acidic peptides, resolved the phosphorylated peptides into two major and one minor phosphorylated spots on the two-dimensional plate (Fig. 3B, bottom panel). These results as well as the three differently charged, phosphorylated species detected in alpha /alpha ' by two-dimensional gel electrophoresis (Fig. 2) suggest that GAD65 exists in a mono, di, and perhaps a triphosphorylated form.

Preliminary observations suggested to us that GAD65 might be phosphorylated in the NH2-terminal region. Thus immunoblotting of phosphorylated GAD65 sometimes revealed degraded fragments of GAD65, which were recognized on Western blots by an antiserum to a COOH-terminal peptide (1701), yet these bands did not show up on the autoradiograms of immunoblots. To further assess the location of the phosphorylated peptides, GAD65 isolated from in vivo 32P-labeled lysates of BHK-77-3 cells, was subjected to a mild trypsin digestion to generate a 58-kDa peptide previously shown to contain amino acids 69/70-585 (28). The 58-kDa fragment, which was positive for immunostaining with the 1701 antiserum (Fig. 4B, panel a), was not phosphorylated (Fig. 4B, panel b), suggesting that the phosphorylation sites reside in the first 69/70 amino acids of GAD65. In the SDS-PAGE analyses of those experiments, most phosphorylated tryptic fragments migrated with the dye front. Tris/Tricine gel electrophoresis of purified GAD65 partially digested with trypsin revealed a small phosphorylated fragment of molecular mass of approximately 8 kDa (Fig. 4B, lanes 5 and 6), which upon exhaustive tryptic digestion resolved into three smaller bands of molecular mass 2-3 kDa (Fig. 4B, lanes 6 and 7). Analyses of the sequence of the first 69/70 amino acids in GAD65 revealed two candidate tryptic fragments in this size range, an NH2-terminal peptide (aa 1-27, mass 2.7 kDa), and a fragment containing aa 44-69 (mass 2.2 kDa, Arg65 is an unlikely cleavage site because it is next to a proline).


Fig. 4. Localization of the phosphorylation site(s) to the amino terminus of GAD65 by one-dimensional tryptic phosphopeptide mapping. A, tryptic degradation map of the NH3 terminus of GAD65. B, separation of tryptic phosphopeptides of GAD65 by SDS-PAGE (panels a and b) and Tris/Tricine gel electrophoresis (panel c). Panel a, immunostaining with the COOH-terminal antibody 1701 of a Western blot of SDS-PAGE of 32P-labeled GAD65 purified from in vivo labeled BHK-77-3 cells and incubated with low concentrations of trypsin at 37 °C for the indicated times. Panel b, autoradiogram of the immunoblot shown in panel a. The 58-kDa COOH-terminal fragment of GAD65 detected by immunoblotting of lane 2, is not phosphorylated (lane 4). Panel c, autoradiogram of 32P-labeled GAD65 purified from BHK-77-3 cells, and incubated with a high concentration of trypsin at 4 °C for 5 min (lane 6) or overnight (O/N) at 37 °C (lane 7). Twice as much sample was loaded in lane 7 to ensure disappearance of the 8-kDa band and detection of any minor fragments present.
[View Larger Version of this Image (54K GIF file)]


GAD65 Is Phosphorylated on Serines 3, 6, 10, and 13

To further characterize the identity of the phosphorylated residues in GAD65, we analyzed the phosphorylation of NH2-terminal deletion mutants of rat GAD65, which have also had the palmitoylated cysteine residues 30 and 45 mutated to alanine (18), as well as substitution mutants of rat GAD65, in which two or three serines in the NH2-terminal region have been mutated to alanine (25). Furthermore, site-directed mutagenesis was used to construct hGAD65 mutants in which serine residues in the NH2-terminal region were individually substituted with alanine.

There are eight serine residues in the first 70 amino acids of hGAD65 at positions 3, 6, 10, 13, 17, 20, 58, and 61. The NH2-terminal region of rat GAD65 also has serines at positions 3, 6, 10, 13, 17, 58, and 61 but has a proline at position 20, and additional serines at positions 52 and 64 (Fig. 5A). The collection of mutants enabled analysis of every serine residue in the first 70 amino acids of GAD65 for phosphorylation.


Fig. 5. GAD65 is phosphorylated on serine residues in the first 15 amino acids of GAD65. Upper panel, autoradiogram of wild-type and mutant rat (lanes 1-7) and human (lanes 8-16). GAD65 immunoprecipitated from transiently transfected and in vivo phosphorylated COS-7 cells and Western blotted to polyvinylidene difluoride membranes. Lower panel, immunostaining of the same Western blots. Substitution of serines 3 and 6 (lane 2) results is a decrease in phosphorylation and additional removal of serines 10 and 13 results in a complete loss of phosphorylation of rat GAD65 (lane 3). Similarly mutation of serines 3 and 6, or serines 10, 13, and 17 to alanine but not mutation of serines 58, 61, and 64 caused a decrease in phosphorylation compared to the wild-type rat protein (lanes 4-7). Consistent with the results with rat mutants, mutation of individual serines 6, 10, and 13 in hGAD65 to alanine results in a decrease in phosphorylation signal and, furthermore, a slight mobility shift, whereas mutation of serine 3 results in a decrease in phosphorylation signal only.
[View Larger Version of this Image (55K GIF file)]


Wild-type and mutant GAD65 plasmids were transiently expressed in COS-7 cells. The corresponding proteins were immunoprecipitated from in vivo 32P-labeled cell lysates, using the GAD6 antibody. This antibody recognizes an epitope in the carboxyl-terminal 41 amino acids of GAD65, which is not affected by the mutations (24, 39). Immunoprecipitates were analyzed by SDS-PAGE and autoradiography (Fig. 5B). The rGAD65 S58A/S61A/S64A mutant did not show a decrease in phosphorylation, strongly suggesting that the phosphorylated residues do not reside in the aa 44-69 fragment of GAD65 (Fig. 5, lanes 6 and 7). In contrast, mutation or deletion of 2-3 serines in the NH2-terminal peptide of rGAD65, affected the phosphorylation of the protein. Thus, a significant decrease in 32P-labeling was observed in a rGAD65 S3A/S6A, rGAD65 S10A/S13A/S17A, and rGAD65 Delta 1-8 mutants (Fig. 5B, lanes 2, 4, and 5), suggesting that the NH2-terminal peptide is phosphorylated on at least 2 serine residues. Furthermore, deletion of the first 15 amino acids in rGAD65, containing serines 3, 6, 10, and 13 abolished phosphorylation. The similar decrease in phosphorylation of the Delta 1-8 mutant, which is lacking serines 3 and 6, but also the palmitoylated cysteines (aa 30 and 45), and the S3A/S6A mutant, which retains the palmitoylation sites, suggested that palmitoylation does not play a role in phosphorylation of GAD65, and this result was confirmed by mutational analysis of hGAD65 (see below).

Analysis of single serine substitution mutants in the NH2-terminal peptide of hGAD65 (Fig. 5B, lanes 8-14) revealed a decrease in phosphorylation signal in the hGAD65 S3A, hGAD65 S6A, hGAD65 S10A, and hGAD65 S13A proteins but not in the hGAD65 S17A and hGAD65 S20A mutants, consistent with polyphosphorylation of serines in the NH2-terminal peptide and suggesting that all 4 serines, 3, 6, 10, 13, can be phosphorylated relatively independently of each other. Interestingly, the S6A, S10A, and S13A mutants also showed a slight increase in mobility on SDS-PAGE. Similar shifts in mobility upon removal of phosphorylation sites have been reported for other proteins (40). Substitution of all 4 serines, 3, 6, 10, and 13 in hGAD65 abolished >= 95% of the phosphorylation signal (Fig. 5, lanes 15 and 16).

The mutational analysis, as well as the two-dimensional phosphopeptide analysis and protein studies, suggest that all four serines residues 3, 6, 10, and 13 can be phosphorylated in combinations to generate mono-, di-, and triphosphorylated GAD65alpha . All these serine residues reside in the same tryptic fragment (aa 1-27). Hence the three spots detected by two-dimensional tryptic phosphopeptide analyses at pH 8.9, are likely to represent the mono-, di-, and triphosphorylated GAD65. The two-dimensional protein analyses reveal three acidic spots which co-migrate with nonphosphorylated alpha  on SDS-PAGE, and one or two spots in alpha ' which align(s) with the most acidic spot(s) in alpha . Since addition of each phosphate group is likely to result in one charge shift, the three increasingly acidic 33P-labeled spots that co-migrate with nonphosphorylated alpha  are likely to represent GAD65alpha phosphorylated on one, two, and three serines, respectively, in a combination that does not result in a significant mobility shift in the SDS-PAGE dimension. Similarly, the spot(s) detected in alpha ', may represent double, and/or triple phosphorylation of serines in GAD65alpha in a combination of serines residues that results in a slight mobility shift in the SDS-PAGE dimension.

Phosphorylation Does Not Affect Km or Vmax for Substrate and Co-enzyme

Bao et al. (41, 42) reported that the enzyme activity of an unspecified soluble isoform of GAD from porcine brain is regulated by phosphorylation. We assessed whether phosphorylation of GAD65 affects Km or Vmax for glutamate and PLP. The analyses for glutamate were carried out using detergent extracts of wild-type and phosphorylation mutants of hGAD65 and rGAD65 expressed in COS-7 cells (Table I). Substitution of the phosphorylated serines in the NH2-terminal domain for alanine either individually or in combinations, that included all serines 3, 6, 10, and 13 in hGAD65, did not affect the Km or Vmax of GAD65 for glutamate (Table I). Deletion of the first 15 amino acids of the rGAD65 resulted in a decrease of Km for glutamate from 1.2 to 0.9 mM. This may, however, reflect a conformational effect of deletion, rather than removal of the phosphorylated residues, since a decrease in Km for glutamate was not observed for the hGAD65 tetraserine mutant.

Table I.

Kinetic constants for glutamate for wild-type and mutant GAD65 proteins

Km and Vmax were determined for mutant and wild-type GAD65 proteins transiently expressed in COS-7 cells. All analyses were done at least in triplicate. The Vmax measured for the wild-type human and rat protein was arbitrarily given a specific activity of 1.0 and values for the mutant proteins were calculated as relative values compared to the activity of the wild-type protein.
Construct Km (mM) (mean ± S.D.) Relative Vmax (mean ± S.D.)

hGAD65 2.15  ± 0.35 1.0
hGAD65 S3A/S6A/S10A/S13A 2.13  ± 0.16 1.0  ± 0.2
rGAD65 1.02  ± 0.15 1.0
rGAD65Delta 1-8 0.81  ± 0.18 1.0  ± 0.1
rGAD65Delta 1-15 0.71  ± 0.13 0.8  ± 0.1
rGAD65 S3A/S6A 1.21  ± 0.18 1.0  ± 0.5
rGAD65 S10A/S13A/S17A 1.26  ± 0.14 1.0  ± 0.3
rGAD65 C30A/C45A 1.08  ± 0.04 1.3  ± 0.4

The analysis for PLP were carried out using wild-type hGAD65 and the S3A/S6A/S10A/S13A mutant. Both proteins showed identical deviations from Michaelis-Menten kinetics at low PLP concentrations. At PLP concentrations between 0.5 and 20 µM PLP, however, both wild-type and the tetraserine GAD65 mutant obeyed Michaelis-Menten kinetics, were identical with regard to Vmax, and displayed an identical Km value of ~0.9 µM.

In summary, phosphorylation does not seem to regulate kinetic properties of GAD65 with regard to glutamate and PLP. It is of note, however, that a detection of subtle effects of phosphorylation on the kinetics of GAD65 may require the separation of phosphorylated, and nonphosphorylated fractions of the wild-type protein and purification of each to homogeneity.

Phosphorylation of GAD65 Is Mediated by a Membrane-associated Kinase and Phosphorylated Protein Remains Largely Membrane-associated

Membrane anchoring of GAD65 is reversible (15, 16), but the factors that regulate the trafficking of the protein between cytosol and membranes are unknown. Washing of isolated membranes in buffers containing enzyme inhibitors results in a stably membrane-associated protein that can only be released from membranes by detergent (15, 16). We analyzed the subcellular localization of phosphorylated GAD65. 32P in vivo labeled BHK-77-3 cells were homogenized, and a postnuclear supernatant separated into cytosolic and crude membrane fractions. The membranes were subjected to a high salt wash. The cytosol, washed membrane fraction, and high salt membrane wash were subjected to Triton X-114 phase separation to analyze the effect of phosphorylation on the hydrophobicity of the protein. GAD65 in the different fractions was analyzed by immunoprecipitation followed by immunoblotting and autoradiography of blots (Fig. 6, panels a and d). As shown previously for the protein in pancreatic beta -cells and transiently transfected COS-7 cells (15, 16, 18), GAD65 is found in the cytosol, membrane wash, and washed particulate fraction of BHK-77-3 cells (Fig. 6, panel d). Similar amounts of total GAD65 were detected in washed membrane and cytosolic fractions (Fig. 6, panel d, compare lanes 1 and 2 with lanes 5 and 6). In contrast, phosphorylated GAD65 was detected either exclusively (results not shown) or predominantly (Fig. 6, panel a) in the washed membrane fraction. We speculated that cytosolic phosphatases might rapidly remove the phosphate from the cytosolic form during homogenization of cells and nuclear spin of lysates. The presence of the phosphatase inhibitors EDTA and/or sodium fluoride throughout the subcellular fractionation procedure, rather than only after the postnuclear spin, did not, however, significantly enhance the detection of phosphorylated GAD65 in the cytosol, which varied between 0 and 20%. Thus the majority of phosphorylated GAD65 remained firmly membrane anchored following subcellular fractionation and a high salt wash of membranes (Fig. 6, panels a and d). Similar data were obtained for the in vitro labeled protein (Fig. 6, panels b and e). Phosphorylation did not seem to affect the distribution of GAD65 into Triton X-114 detergent and aqueous phases indicating that phosphorylation does not significantly alter the hydrophobicity of GAD65 (Fig. 6, compare upper and lower panels).


Fig. 6. Phosphorylated GAD65 is predominantly localized in membranes in BHK-77-3 cells and phosphorylation is mediated by a membrane associated kinase. Upper panels are autoradiograms of the immunoblots shown in the lower panels. Panels a and d, GAD65 immunoprecipitated from Triton X-114 detergent phase (d) and aqueous phase (a) separated cytosolic (CYTO), washed membrane (MEM), and a high salt membrane wash (WASH) fraction prepared from in vivo phosphorylated BHK-77-3 cells homogenized in lysis buffer containing 5 mM EDTA and 5 mM sodium fluoride. Immunoprecipitates were subjected to SDS-PAGE followed by immunoblotting and autoradiography. Panels b and e, GAD65 immunoprecipitated from the same fractions isolated from in vitro phosphorylated BHK-77-3 cells. Panels c and f, GAD65 immunoprecipitated from cytosolic and membrane fractions which were prepared from BHK-77-3 cells and then subjected to in vitro phosphorylation.
[View Larger Version of this Image (43K GIF file)]


In another set of experiments, membranes and cytosol from unlabeled BHK-77-3 cells were separated before in vitro labeling with [32P]ATP (Fig. 6, panel d). In these experiments equal amounts of GAD65 were present in membranes and cytosolic fractions. 32P labeling was only detected in GAD65 in the membrane fraction demonstrating that GAD65 is phosphorylated by a membrane bound kinase. The subcellular fractionation data show that phosphorylation of GAD65 takes place exclusively in a membrane compartment(s), and that stably phosphorylated protein remains membrane associated.

To address the question whether phosphorylation affects the subcellular localization of GAD65, we analyzed the subcellular distribution of wild-type hGAD65 and the hGAD65 S3A/S6A/S10A/S13A mutant, transiently expressed in COS-7 cells, BHK-21 cells, PC12 cells, and in an insulinoma cell line beta TC3 (27). The tetraserine mutant was not phosphorylated in these cell lines (Fig. 7, lane 4, and results not shown). No difference was detected in the subcellular distribution, nor the hydrophobicity of the wild-type and the nonphosphorylated mutant in any of these cell lines (Fig. 7, lanes 5-16 and results not shown). Thus phosphorylation does not seem to affect the membrane association of GAD65 in endocrine or non-endocrine cell lines.


Fig. 7. Substitution of the phosphorylated serines 3, 6, 10, and 13 for alanine does not affect membrane association in beta TC3 cells. Wild-type hGAD65 and the hGAD54 S3A/S6A/S10A/S13A mutant, transiently expressed in beta TC3 cells, were immunoprecipitated from cellular lysates of in vivo phosphorylated cells (lanes 1-4), and from Triton X-114 detergent phase (d) and aqueous phase (a) separated cytosolic (CYTO), washed membrane (MEM), and a high salt membrane wash (WASH) fractions prepared from cells (lanes 5-16). Immunoprecipitates were subjected to SDS-PAGE followed by immunoblotting. Removal of the serine phosphorylation sites abolished phosphorylation of GAD65 in beta TC3 cells (lanes 1-4) but did not affect the membrane association of the protein in these cells (lanes 5-16).
[View Larger Version of this Image (31K GIF file)]



DISCUSSION

We have demonstrated that GAD65 expressed in a variety of cell lines is phosphorylated both in vitro and in vivo. Phosphorylation is mediated by a membrane bound kinase, and the phosphorylated protein seems to remain largely membrane associated. This study provides the first evidence that the membrane bound form of GAD65 is phosphorylated. Phosphorylation as well as palmitoylation thus distinguish the membrane bound and soluble forms of the enzyme.

The identity of the phosphorylated protein as GAD65 was established by several criteria. First, the 32P-labeled protein was immunoprecipitated with a GAD65 specific antibody (GAD6), but not with control antibodies. Second, the phosphorylated protein was recognized by a second GAD antibody (1701) on Western blots of immunoprecipitates. Third, the phosphorylated protein was absent in parent cell lines negative for GAD65, and finally, two-dimensional gel electrophoretic analysis of the phosphorylated protein revealed the well characterized charge and size coordinates of GAD65 from pancreatic beta -cells and neurons (8, 15, 23, 24). Phosphorylated GAD65 co-migrated with the alpha  component of the GAD65 alpha /beta doublet described earlier (15, 16, 23) and with a weaker more slowly migrating band on SDS-PAGE, alpha ', but was not detected in GAD65beta . Phosphorylation is the first modification shown to be unique to GAD65alpha .

GAD65 is polyphosphorylated on the NH2-terminal serine residues 3, 6, 10, and 13. Interestingly, exon 1 (aa 1-25), which encodes the phosphorylated region of GAD65, as well as exons 2 (aa 26-40) and 3 (aa 46-95), share no homology with the analogous regions of the larger isoform of glutamate decarboxylase, GAD67, although the two proteins are 78% identical in the remaining sequences. Thus it seems likely that the phosphorylation of NH2-terminal serines in GAD65 shown here is unique for this isoform.

Two-dimensional NEPHGE/SDS-PAGE analysis of intact GAD65 confirmed the presence of multiple phosphorylated species, and allowed their further characterization. The two-dimensional gel electrophoretic analyses of GAD65 also revealed a heterogeneity in the SDS-PAGE mobility of the two most acidic phosphorylated species, corresponding to the alpha ' band detected by one-dimensional SDS-PAGE. Since alanine substitutions of individual serine residues in the NH2-terminal region of GAD65 affected the SDS-PAGE mobility of the protein to a different degree, we propose that the 33P-labeled spots detected in alpha  and alpha ' represent phosphorylation of different combinations of serine residues 3, 6, 10, and 13.

The nature of differences between the alpha  and beta  forms of GAD65 is unknown. Both alpha  and beta  are palmitoylated and analyses of hydrophobicity and subcellular localization of GAD65 have not revealed differences in those parameters between alpha  and beta  (16). SDS-PAGE analysis of the protein under nonreducing conditions reveals only a single band with the mobility of GAD65 alpha . Addition of increasing concentrations of beta -mercaptoethanol is accompanied by the appearance of the beta -band, suggesting that the oxidation and/or folding state of the two forms may differ.2 The two-dimensional gel electrophoretic analyses show that phosphorylation is not the cause of the alpha /beta heterogeneity, since both exist in a nonphosphorylated form. Rather, phosphorylation seems to be an exclusive property of GAD65alpha . GAD65beta is not phosphorylated and yet consistently displays an identical acidic charge heterogeneity on two-dimensional gels as alpha . Based on those results, we propose that alpha  and beta  constitute the two subunits of the native non-disulfide linked GAD65 dimer, and that the protein remains as a dimer in the conditions of the NEPHGE analyses of the first dimension, but then falls apart in the strongly dissociating conditions of the second dimensional SDS-PAGE. Thus studies of native GAD65 would analyze the alpha /beta dimer as one entity and not discern potential differences in the chemical and physical parameters of the two subunits. This model is consistent with the inability of earlier studies to detect differences in Triton X-114 partition patterns of alpha  and beta , in spite of their distinct phosphorylation, and the consequent anticipated increase in the hydrophilicity of alpha  (15, 16).

The charge shift separation of phosphorylated and non-phosphorylated spots by two-dimensional NEPHGE/SDS-PAGE allow us to roughly estimate the stoichiometry of GAD65 phosphorylation. Based on several two-dimensional experiments, we estimate that 20-40% of total GAD65 in BHK-77-3 cells is phosphorylated, corresponding to 30-60% of the membrane anchored protein.

A common biological function of protein phosphorylation is regulation of enzymatic activity. Bao et al. (41, 42) reported that phosphorylation of a soluble, nonidentified GAD isoform from brain by cAMP-dependent kinase (PKA) caused a decrease in enzyme activity, which could be reversed by treatment of the protein with calcineurin. We determined the Vmax and Km for wild-type GAD65 as well as a series of phosphorylation mutants in cell free lysates generated from transfected COS-7 cells. In our studies, a decrease or loss in phosphorylation observed for the serine substitution mutants did not result in a detectable effect on the Vmax and Km for glutamate or PLP. Furthermore, several lines of evidence suggest that the kinase involved in phosphorylation of GAD65 is not PKA. First, the phosphorylation site we have identified does not contain a PKA consensus sequence; second, the addition of cAMP or staurosporin (a cAMP-dependent kinase inhibitor) to our in vitro labeling reactions did not affect the degree of phosphorylation of GAD65; third, we were unable to detect phosphorylation of purified GAD65 in vitro by PKA. In contrast GAD67 can be phosphorylated by PKA in similar conditions.3 We therefore suggest that the phosphorylation reported by Bao et al. (41, 42) may be a characteristic of the cytosolic isoform, GAD67.

Phosphorylation can play a role in the regulation of membrane association of proteins. Addition of phosphate groups can decrease the membrane avidity of proteins by charge repulsion from membrane phospholipids. Hence phosphorylation of a membrane protein can facilitate its translocation to the cytosol (Ref. 43 and references therein). Conversely, phosphorylation of a cytosolic protein can block its membrane association and retain it in the cytosol (44). GAD65 is an amphiphilic molecule which is isolated in a hydrophilic soluble form, a hydrophobic soluble form, and a hydrophobic firmly membrane anchored form (15, 16). The membrane anchoring of GAD65 is reversible (16). The phosphorylated NH2-terminal peptide is proximal to the region of GAD65 that undergoes a set of hydrophobic modifications and is implicated in the membrane anchoring of the protein (16, 18, 45).

The mechanism of membrane anchoring of GAD65 is not known. Palmitoylation of cysteines 30 and 45 is an exclusive property of membrane anchored GAD65 and was originally proposed to be involved in membrane anchoring (16). However, site-directed mutagenesis of the palmitoylated cysteines does not affect the distribution of the protein between cytosol and membrane compartments in COS-7 cells (18). Palmitoylation is therefore not critical for membrane anchoring, but may assist in targeting GAD65 to the right membrane compartment, and/or play a role in protein-protein interaction in synaptic vesicle membranes. Deletion of amino acids 1-23 in GAD65 and concomitant mutation of the palmitoylated cysteines also does not affect the distribution of the protein between soluble and membrane compartments in COS-7 cells. However, removal of the next 8 amino acids (aa 24-31) abolishes membrane anchoring (18). Studies of GAD65/GAD67 chimeras suggest that a substitution of the first 29 amino acids of GAD67 with the first 27 amino acids of GAD65 is sufficient to target the normally cytosolic GAD67 isoform to the perinuclear membrane compartment in CHO cells (45). Thus amino acids 24-27 seem to be critical for membrane anchoring of GAD65. Because of the proximity of the phosphorylated serine residues to the region implicated in membrane anchoring of GAD65, we speculated that phosphorylation might be a mechanism by which GAD65 is released from membranes. To address this possibility, subcellular fractionation experiments were performed on in vivo or in vitro phosphorylated GAD65. These experiments revealed that phosphorylated GAD65 is predominantly localized in membrane compartments, despite the fact that 40-50% of total GAD65 is recovered in the cytosol. A prominent fraction of membrane associated GAD65 (30-60%) was phosphorylated in our experiments. Yet high salt wash of membranes in the presence of phosphatase inhibitors did not release the phosphorylated protein, strongly suggesting that phosphorylation is either not involved in dissociation of GAD65 from membranes, or if required, it is not sufficient for release.

Phosphorylation could play a role in membrane association by mediating association of soluble GAD65 with a membrane protein, thus targeting it to a specific membrane compartment where it can undergo lipid modification(s) by a membrane associated enzyme and become firmly membrane anchored. Two lines of evidence argue against this possibility. First, the hGAD65 S3A/S6A/S10A/S13A in which phosphorylation is almost completely abolished, is membrane anchored similar to wild-type GAD65 in transiently transfected COS-7 cells, beta TC3 cells, BHK-21 cells, and PC12 cells, and similar results have been obtained for the rGAD65 Delta 1-15 phosphorylation mutant, and the deletion and substitution mutants, which show a significant decrease in phosphorylation in COS-7 cells (Refs. 18 and 25, and this study) demonstrating that phosphorylation of GAD65 is not required for membrane anchoring in those cells. Second, in vitro phosphorylation experiments using separated membrane and cytosolic fractions of BHK-77-3 in the presence of phosphatase inhibitors, showed that GAD65 was exclusively phosphorylated in the membrane fraction. Thus phosphorylation is not involved in anchoring cytosolic GAD65 to membranes, but is an independent modification caused by a membrane associated kinase, and restricted to the fraction of the enzyme, which is already membrane anchored.

In summary we have demonstrated that the membrane bound form of GAD65 is phosphorylated on multiple serine residues in the NH2-terminal domain and that this modification is restricted to GAD65alpha . The biological function of this modification remains to be established. Phosphorylation of GAD65 does not appear to alter its kinetic behavior with respect to the substrate glutamate, or the co-enzyme PLP, nor does it appear to be involved in the membrane anchoring of the protein in transiently transfected cells.

By necessity, we have studied the effect of phosphorylation of GAD65 on membrane anchoring and enzyme activity in recombinant cell lines. The role of phosphorylation of the enzyme in its natural environment, neurons and primary pancreatic beta -cells, may be distinct and perhaps become accessible in the future by genetic manipulations in the mouse.

We speculate that phosphorylation of membrane anchored GAD65 is involved in regulating or facilitating a specific function of the enzyme in synaptic vesicle membranes. One possibility is that phosphorylation mediates interaction of GAD65 with regulatory proteins in the synaptic vesicle membrane or facilitates transport of the product GABA to the lumen of vesicles by docking the enzyme to a hypothetical GABA transporter.


FOOTNOTES

*   This study was supported in part by National Institutes of Health Grant DK41822. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   Supported by a fellowship from the Human Frontier of Science Program.
   To whom correspondence should be addressed: Hormone Research Institute, University of California San Francisco, 513 Parnassus Ave., San Francisco, CA 94143-0534. Tel.: 415-476-6267; Fax: 415-502-1447; E-mail: s_baekkeskov{at}quickmail.ucsf.edu.
1    The abbreviations used are: GAD glutamic acid decarboxylase; AET, 2-aminoethylisothiouronium bromide; BHK, baby hamster kidney; GABA, gamma -aminobutyric acid; hGAD65, human GAD65; NEPHGE, non-equilibrium pH-gradient gel electrophoresis; PKA, cAMP-dependent kinase; PLP, pyridoxal 5'-phosphate; rGAD65, rat GAD65; TLE, thin layer electrophoresis; PAGE, polyacrylamide gel electrophoresis; Tricine, N-[2-hydroxy-1,1-bis-(hydroxymethyl)ethyl]glycine.
2    J. S. Petersen and S. Baekkeskov, unpublished results.
3    M. Namchuk and S. Baekkeskov, unpublished results.

REFERENCES

  1. Roberts, E. (1986) in Benzodiazepine/GABA Receptors and Chloride Channels: Structural and Functional Properties (Olson, R. W., and Venter, C. J., eds), pp. 1-39, Alan R. Liss, Inc., New York
  2. Okada, Y., Taniguchi, H., and Shimada, C. (1976) Science 194, 620-622 [Medline] [Order article via Infotrieve]
  3. Rorsman, P., Berggren, P. O., Bokvist, K., Ericson, H., Mohler, H., Ostenson, C.-G., and Smith, P. A. (1989) Nature 341, 233-236 [CrossRef][Medline] [Order article via Infotrieve]
  4. Baxter, C. F. (1970) in Handbook of Neurochemistry (Lajtha, A., ed), Vol. 3, pp. 289-353, Plenum Press, New York
  5. Baxter, C. F. (1976) in GABA in Nervous System Function (Roberts, E., Chase, T. N., and Tower, D. B., eds), pp. 61-87, Raven Press, New York
  6. Erlander, M. G., Tillakaratne, N. J., Feldbloom, S., Patel, N., and Tobin, A. J. (1991) Neuron 7, 91-100 [Medline] [Order article via Infotrieve]
  7. Bu, D. F., Erlander, M. G., Hitz, B. C., Tillakaratne, N. J. K., Kaufman, D. L., Wagner-McPherson, C. B., Evans, G. A., and Tobin, A. J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2115-2119 [Abstract]
  8. Baekkeskov, S., Aanstoot, H.-J., Christgau, S., Reetz, A., Solimena, M., Cascalho, M., Folli, F., Richter-Olesen, H., and De Camilli, P. (1990) Nature 347, 151-156 [CrossRef][Medline] [Order article via Infotrieve]
  9. Tisch, R., Yang, X.-D., Singer, S. M., Liblau, R. S., Fugger, L., and McDevitt, H. O. (1993) Nature 366, 72-75 [CrossRef][Medline] [Order article via Infotrieve]
  10. Kaufman, D. L., Clare-Salzler, M., Tian, J., Forsthuber, T., Ting, G. S. P., Robinson, P., Atkinson, M. A., Sercarz, E. E., Tobin, A. J., and Lehmann, P. V. (1993) Nature 366, 69-72 [CrossRef][Medline] [Order article via Infotrieve]
  11. Solimena, M., Folli, F., Aparisi, R., Pozza, G., and De Camilli, P. (1990) N. Engl. J. Med. 322, 1555-1560 [Abstract]
  12. Miller, L. P., Walters, J. R., Eng, M., and Martin, D. L. (1980) Brain Res. Bull. 5, 89-94
  13. Itoh, M., and Uchimura, H. (1981) Neurochem. Res. 6, 1283-1289 [Medline] [Order article via Infotrieve]
  14. Martin, D. L., Martin, S. B., Wu, S. J., and Espina, N. (1991) J. Neurosci. 11, 2725-2731 [Abstract]
  15. Christgau, S., Schierbeck, H., Aanstoot, H.-J., Aagaard, L., Begley, K., Kofod, H., Hejnaes, K., and Baekkeskov, S. (1991) J. Biol. Chem. 266, 21257-21264 [Abstract/Free Full Text]
  16. Christgau, S., Aanstoot, H.-J., Schierbeck, H., Begley, K., Tullin, S., Hejnaes, H., and Baekkeskov, S. (1992) J. Cell Biol. 118, 309-320 [Abstract]
  17. Reetz, A., Solimena, M., Matteoli, M., Folli, F., Takei, K., and DeCamilli, P. (1991) EMBO J. 10, 1275-1284 [Abstract]
  18. Shi, Y., Veit, B., and Baekkeskov, S. (1994) J. Cell Biol. 124, 927-934 [Abstract]
  19. Porter, T. G., and Martin, D. L. (1984) J. Neurochem. 43, 1464-1467 [Medline] [Order article via Infotrieve]
  20. Blindermann, J. M., Maitre, M., Ossola, L., and Mandel, P. (1978) Eur. J. Biochem. 86, 143-152 [Abstract]
  21. Spink, D. C., Porter, T. G., Wu, S. J., and Martin, D. L. (1985) Biochem. J. 231, 695-703 [Medline] [Order article via Infotrieve]
  22. Legay, F., Henry, S., and Tappaz, M. (1987) J. Neurochem. 48, 1022-1026 [Medline] [Order article via Infotrieve]
  23. Baekkeskov, S., Warnock, G., Christie, M., Rajotte, R. V., Mose-Larsen, P., and Fey, S. (1989) Diabetes 38, 1133-1141 [Abstract]
  24. Kim, J., Richter, W., Aanstoot, H.-J., Shi, Y., Fu, Q., Rajotte, R., Warnock, G., and Baekkeskov, S. (1993) Diabetes 42, 1799-1808 [Abstract]
  25. Shi, Y., and Baekkeskov, S. (1995) in Diabetes 1994 (Baba, S., and Kaneko, T., eds), pp. 111-115, Elsevier Scientific, Amsterdam
  26. Kunkel, T. A., Roberts, J. D., and Zakour, R. A. (1987) Methods Enzymol. 154, 367-382 [Medline] [Order article via Infotrieve]
  27. Efrat, S., Linde, S., Kofod, H., Spector, D., Delannoy, M., Grant, S., Hanahan, D., and Baekkeskov, S. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 9037-9041 [Abstract]
  28. Karlsen, A. E., Hagopian, W. A., Petersen, J. S., Boel, E., Dyrberg, T., Grubin, C. E., Michelsen, B. K., Madsen, O. D., and Lernmark, Å. (1992) Diabetes 41, 1355-1359 [Abstract]
  29. Bonzelius, F., Herman, G. A., Cardone, M. H., Mostov, K. E., and Kelly, R. B. (1994) J. Cell. Biol. 127, 1603-1616 [Abstract]
  30. Kim, J., Namchuk, M., Bugawan, D., Fu, Q., Jaffe, M., Shi, Y., Aanstoot, H.-J., Turck, C., Erlich, H., Lennon, V., and Baekkeskov, S. (1994) J. Exp. Med. 180, 595-606 [Abstract]
  31. Pan, E. Y.-C., and Li, S. S.-L. (1982) Int. J. Peptide Protein Res. 20, 177-187 [Medline] [Order article via Infotrieve]
  32. Aanstoot, H.-J., Sigurdsson, E., Shi, Y., Christgau, S., Grobbee, D., Bruining, G. J., Molenaar, J. L., Hofman, A., and Baekkeskov, S. (1994) Diabetologia 37, 917-924 [CrossRef][Medline] [Order article via Infotrieve]
  33. Smith, J. A. (1995) in Current Protocols in Molecular Biology (Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K., eds), Vol. 2, pp. 10.5.1-10.5.5, John Wiley & Sons, Inc., New York
  34. Boyle, W. J., van der Geer, P., and Hunter, T. (1991) Methods Enzymol. 201, 110-149 [Medline] [Order article via Infotrieve]
  35. Schagger, H., and von Jagow, G. (1987) Anal. Biochem. 166, 368-379 [Medline] [Order article via Infotrieve]
  36. Bordier, C. (1981) J. Biol. Chem. 256, 1604-1607 [Abstract/Free Full Text]
  37. Leatherbarrow, R. J. (1992) GraFit version 3.0, Erithacus Software Ltd., Staines, United Kingdom
  38. Cooper, J. A. (1991) Methods Enzymol. 201, 251-261 [Medline] [Order article via Infotrieve]
  39. Richter, W., Shi, Y., and Baekkeskov, S. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2832-2836 [Abstract]
  40. Lazarowski, E. R., Winegar, D. A., Nolan, R. D., Oberdisse, E., and Lapetina, E. G. (1990) J. Biol. Chem. 265, 13118-13123 [Abstract/Free Full Text]
  41. Bao, J., Nathan, B., Hsu, C.-C., Zhang, Y., Wu, R., and Wu, J.-Y. (1994) J. Biomed. Sci. 1, 237-244 [Medline] [Order article via Infotrieve]
  42. Bao, J., Cheung, W. Y., and Wu, J.-Y. (1995) J. Biol. Chem. 270, 6464-6467 [Abstract/Free Full Text]
  43. Allen, L.-A. H., and Aderem, A. (1995) EMBO J. 14, 1109-1121 [Abstract]
  44. van der Sluijs, P., Hull, M., Huber, L. A., Male, P., Goud, B., and Mellman, I. (1992) EMBO J. 11, 4379-4389 [Abstract]
  45. Solimena, M., Dirkx, R., Jr., Radzynski, M., Mundigl, O., and De Camilli, P. (1994) J. Cell Biol. 126, 331-341 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.